Epping-Jordan, M.P.; Girard, F.; Bessis, A.-S.; Mutel, V.; Boléa, C.; Derouet, F.; Bessif, A.; Mingard, B.; Barbier, S.; Paradis, J.S.;
et al. Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease. Cells 2023, 12, 1004.
https://doi.org/10.3390/cells12071004
AMA Style
Epping-Jordan MP, Girard F, Bessis A-S, Mutel V, Boléa C, Derouet F, Bessif A, Mingard B, Barbier S, Paradis JS,
et al. Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease. Cells. 2023; 12(7):1004.
https://doi.org/10.3390/cells12071004
Chicago/Turabian Style
Epping-Jordan, Mark P., Françoise Girard, Anne-Sophie Bessis, Vincent Mutel, Christelle Boléa, Francis Derouet, Abdelhak Bessif, Brice Mingard, Stéphanie Barbier, Justine S. Paradis,
and et al. 2023. "Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease" Cells 12, no. 7: 1004.
https://doi.org/10.3390/cells12071004
APA Style
Epping-Jordan, M. P., Girard, F., Bessis, A. -S., Mutel, V., Boléa, C., Derouet, F., Bessif, A., Mingard, B., Barbier, S., Paradis, J. S., Rocher, J. -P., Lütjens, R., Kalinichev, M., & Poli, S.
(2023). Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease. Cells, 12(7), 1004.
https://doi.org/10.3390/cells12071004
